Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naive Neovascular Age-related Macular Degeneration (nAMD) Patients

Trial Profile

A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naive Neovascular Age-related Macular Degeneration (nAMD) Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary) ; Aflibercept
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms UNRAVEL
  • Sponsors Novartis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 14 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top